Brief: Arch Biopartners’ Lead Drug Lsalt Peptide To Enter The Canadian Treatments For Covid-19 (Catco) Trial
01/12/2021 13:16
Dec 1 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS’ LEAD DRUG LSALT PEPTIDE TO ENTER THE
CANADIAN
TREATMENTS FOR COVID-19 (CATCO) TRIAL
Source text for Eikon: ID:nGNXc7jldw
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide